The Data Safety Monitoring Board (DSMB) has “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.” READ MORE
Tuesday 23 March 2021
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment